Sanjivani Paranteral Ltd. (SANJIVIN) Share Price Rises 10.9% Today
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Sanjivani Paranteral Ltd. Share Price rises 10.9% to Rs 177 today, marking a significant gain in the micro-cap category.
Sanjivani Paranteral Ltd. Share Price has experienced a notable rise today, reaching Rs 177, which represents a 10.9% increase from the previous close of Rs 159.6. This surge places the company’s market capitalisation at Rs 202.51 crore, categorising it within the micro-cap segment.
The stock opened at Rs 160 and quickly gained momentum, reaching a high of Rs 177 and a low of Rs 155 during the trading session. The total turnover for the day was Rs 0.18 crore, with a volume of 10,314 shares traded on the BSE. This volume indicates a strong participation level, reflecting heightened investor activity in Sanjivani Paranteral Ltd. Share Price today.
Sanjivani Paranteral Ltd. (SANJIVIN) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 177 |
| Previous Close | Rs 159.6 |
| Today's Change | +Rs 17.4 (+10.9%) |
| Day Open | Rs 160 |
| Day High | Rs 177 |
| Day Low | Rs 155 |
| Current Volume (BSE) | 10,314 |
| BSE Traded Volume | 10,314 |
| Combined NSE + BSE Volume | 10,314 |
| Turnover | Rs 0.18 crore |
| Market Capitalisation | Rs 202.51 crore |
| Market Cap Category | Micro Cap |
Sanjivani Paranteral Ltd. (SANJIVIN) traded at Rs 177. versus the previous close of Rs 159.6, a rise of 10.9%. The stock opened at Rs 160, reached Rs 177, touched Rs 155. Reported volume was 10,314.
Sanjivani Paranteral Ltd. (SANJIVIN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 202.51 crore |
| P/E Ratio | 28.89x |
| P/B Ratio | 4.06x |
| ROE | 0% |
| ROCE | 266.43% |
| EPS | Rs 5.52 |
| Dividend Yield | 0% |
Sanjivani Paranteral Ltd. was valued at a P/E ratio of 28.89x, a P/B ratio of 4.06x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 0% and ROCE of 266.43%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 5.52, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
From a fundamental perspective, Sanjivani Paranteral Ltd. presents a mixed picture. The company’s market capitalisation stands at Rs 202.51 crore, placing it in the micro-cap category. The price-to-earnings (P/E) ratio is 28.89, which is above the sector median of 25.82 but below the average of 80.86, indicating a moderate valuation relative to its peers.
The price-to-book (P/B) ratio is 4.06, significantly higher than the sector median of 1.85, suggesting that the stock may be valued at a premium compared to its industry peers. The return on equity (ROE) is 0, which is below the sector median of 10.59, indicating potential challenges in generating returns for shareholders.
However, the return on capital employed (ROCE) is exceptionally high at 266.43, far exceeding the sector median of 12.98. This indicates that the company is effectively utilizing its capital to generate returns. The earnings per share (EPS) is Rs 5.52, providing a measure of the company’s profitability on a per-share basis.
While the dividend yield is 0, suggesting no current payout to shareholders, the strong ROCE and moderate P/E ratio may still attract investors looking for growth potential in the healthcare sector.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 28.89x |
| Benchmark Median P/E | 25.82x |
| Benchmark Average P/E | 80.86x |
| Benchmark P/E Range | 3.39x to 3,385.56x |
| Company P/B Ratio | 4.06x |
| Benchmark Median P/B | 1.85x |
| Company ROE | 0% |
| Benchmark Median ROE | 10.59% |
| Company ROCE | 266.43% |
| Benchmark Median ROCE | 12.98% |
| Company Market Capitalisation | Rs 202.51 crore |
| Benchmark Median Market Cap | Rs 146.67 crore |
Sanjivani Paranteral Ltd. (SANJIVIN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Sanjivani Paranteral Ltd. (SANJIVIN) has a P/E ratio of 28.89x, which is above the benchmark median of 25.82x, a difference of +11.89%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sanjivani Paranteral Ltd. (SANJIVIN) has a ROE of 0%, which is below the benchmark median of 10.59%, a difference of -100%. Sanjivani Paranteral Ltd. (SANJIVIN) has a ROCE of 266.43%, which is above the benchmark median of 12.98%, a difference of +1,952.62%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Sanjivani Paranteral Ltd. operates within the healthcare sector, specifically in the pharmaceuticals and drugs industry. The sector comprises 137 companies, with the company’s P/E ratio of 28.89 sitting above the sector median of 25.82 but below the average of 80.86. This places Sanjivani Paranteral Ltd. in a competitive position within its industry.
The company’s P/B ratio of 4.06 is notably higher than the sector median of 1.85, indicating a premium valuation. The ROE of 0 is below the sector median of 10.59, while the ROCE of 266.43 is significantly higher than the sector median of 12.98, highlighting the company’s efficient capital utilization.
The healthcare sector, particularly pharmaceuticals, has been a focus for investors due to its potential for growth and innovation. Sanjivani Paranteral Ltd.’s performance today aligns with this trend, as the company continues to capture investor interest despite its mixed fundamental metrics.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,945.17 | 30.21 | 0.44 | -2.89 | -0.26 |
| Hikal Ltd. | HIKAL | 2,835.92 | 0 | 2.35 | 15.22 | 16.15 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,652.68 | 39.86 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,608.51 | 63.2 | 10 | 18.65 | 22.17 |
| Panacea Biotec Ltd. | PANACEABIO | 2,589.99 | 0 | 3.07 | 0 | 5.36 |
Sanjivani Paranteral Ltd. (SANJIVIN) has a P/E ratio of 28.89x compared with the displayed peer median of 30.21x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 266.43% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Sanjivani Paranteral Ltd. (SANJIVIN) has a market capitalisation of Rs 202.51 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
In comparison to its peers, Sanjivani Paranteral Ltd. exhibits a unique profile. Its P/E ratio of 28.89 is lower than Kwality Pharmaceuticals Ltd.’s 39.86 but higher than Venus Remedies Ltd.’s 17.74. The company’s P/B ratio of 4.06 is higher than Hikal Ltd.’s 2.35, indicating a premium valuation.
While the ROE is 0, the ROCE of 266.43 is significantly higher than peers like Beta Drugs Ltd., which has a ROCE of 22.17. This suggests that Sanjivani Paranteral Ltd. is effectively utilizing its capital compared to its competitors.
With a market capitalisation of Rs 202.51 crore, Sanjivani Paranteral Ltd. is smaller than its peers, such as Dishman Carbogen Amcis Ltd., which has a market cap of Rs 2945.17 crore. This size difference may influence investor perception and risk appetite.
Why Investors Are Watching Sanjivani Paranteral Ltd.
Investors are closely monitoring Sanjivani Paranteral Ltd. due to its significant price rise today and its position within the healthcare sector. The company’s strong technical momentum and efficient capital utilization are key points of interest.
- Price Action: 10.9% rise to Rs 177, surpassing micro-cap threshold.
- Technical Position: Strong RSI at 62.91, indicating upward momentum.
- Fundamental Context: High ROCE of 266.43, moderate P/E ratio.
- Sector Positioning: Operates in a growth-focused healthcare sector.
Investors should continue to monitor Sanjivani Paranteral Ltd. for any further developments in its price action and sector performance. The company’s ability to maintain its momentum and capitalize on sector trends will be crucial in the coming months.
About Sanjivani Paranteral Ltd.
Sanjivani Paranteral Ltd. is a player in the healthcare sector, specifically within the pharmaceuticals and drugs industry. The company focuses on the development and manufacturing of pharmaceutical products, catering to a diverse range of therapeutic areas.
Operating in a competitive industry, Sanjivani Paranteral Ltd. aims to leverage its expertise in drug formulation and production to meet the growing demand for healthcare solutions. The company’s strategic focus on innovation and quality positions it as a potential growth player in the sector.
With a market capitalisation of Rs 202.51 crore, Sanjivani Paranteral Ltd. is classified as a micro-cap company, offering investors exposure to the dynamic and evolving healthcare landscape.
Track Sanjivani Paranteral Ltd. Share Price on Univest
Use Sanjivani Paranteral Ltd. (SANJIVIN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors and market enthusiasts can track Sanjivani Paranteral Ltd. Share Price on Univest for real-time updates. Univest provides comprehensive insights into the company’s technical indicators, fundamental ratios, shareholding patterns, and market trends.
Stay informed about Sanjivani Paranteral Ltd.’s performance and market movements by accessing detailed analysis and data on Univest. This platform offers valuable tools for investors seeking to make informed decisions in the dynamic stock market environment.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Sanjivani Paranteral Ltd.?
Ans. The current share price of Sanjivani Paranteral Ltd. is Rs 177, reflecting a 10.9% increase from the previous close of Rs 159.6. The stock moved 10.9% during the session. The intraday range extended from Rs 155 to Rs 177.
How much did Sanjivani Paranteral Ltd. share price rise today?
Ans. Sanjivani Paranteral Ltd. share price rose by 10.9% today, reaching Rs 177 from the previous close of Rs 159.6. The stock moved 10.9% during the session. The intraday range extended from Rs 155 to Rs 177.
What is the market capitalisation of Sanjivani Paranteral Ltd.?
Ans. The market capitalisation of Sanjivani Paranteral Ltd. is Rs 202.51 crore, categorizing it as a micro-cap company. The company operates in the Healthcare sector. Its P/E ratio is 28.89x. ROE is 0% and ROCE is 266.43%.
What is the P/E ratio of Sanjivani Paranteral Ltd.?
Ans. The P/E ratio of Sanjivani Paranteral Ltd. is 28.89, which is above the sector median of 25.82. The company trades at a P/E ratio of 28.89x. Its P/B ratio is 4.06x.
What is the ROCE of Sanjivani Paranteral Ltd.?
Ans. The ROCE of Sanjivani Paranteral Ltd. is 266.43, significantly higher than the sector median of 12.98. ROE stands at 0%. ROCE stands at 266.43%. The relevant peer median ROE is 10.59%.
How does Sanjivani Paranteral Ltd. compare to its peers?
Ans. Sanjivani Paranteral Ltd. has a P/E of 28.89 and a ROCE of 266.43, differing from peers like Kwality Pharmaceuticals Ltd. with a P/E of 39.86. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals Ltd.
